<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title>Critical Care</journal-title><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19014570</article-id><article-id pub-id-type="pmc">2646351</article-id><article-id pub-id-type="publisher-id">cc7117</article-id><article-id pub-id-type="doi">10.1186/cc7117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Malliotakis</surname><given-names>Polychronis</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>malliot@altecnet.gr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Linardakis</surname><given-names>Manolis</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>linman@med.uoc.gr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Gavriilidis</surname><given-names>George</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>giogav@hotmail.com</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Georgopoulos</surname><given-names>Dimitris</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>georgop@med.uoc.gr</email></contrib></contrib-group><aff id="I1"><label>1</label>Intensive Care Medicine Department, University Hospital of Heraklion, University of Crete, PO Box 1352, 71110 Heraklion, Crete, Greece</aff><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2008</year></pub-date><volume>12</volume><issue>6</issue><fpage>R140</fpage><lpage>R140</lpage><ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/12/6/R140"/><history><date date-type="received"><day>18</day><month>6</month><year>2008</year></date><date date-type="rev-request"><day>20</day><month>7</month><year>2008</year></date><date date-type="rev-recd"><day>4</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Malliotakis et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Malliotakis et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Malliotakis
               Polychronis
               
               malliot@altecnet.gr
            </dc:author><dc:title>
            Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Critical Care 12(6): R140-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1364-8535(2008)12:6&#x0003c;R140&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1364-8535</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Introduction</title><p>Delivery of bronchodilators with a metered-dose inhaler (MDI) and a spacer device in mechanically ventilated patients has become a widespread practice. However, except for the short-acting &#x003b2;2-agonist salbutamol, the duration of action of other bronchodilators, including long-acting &#x003b2;2-agonists, delivered with this technique is not well established. The purpose of this study was to examine the duration of bronchodilation induced by the long-acting &#x003b2;2-agonist salmeterol administered with an MDI and a spacer in a group of mechanically ventilated patients with exacerbation of chronic obstructive pulmonary disease (COPD).</p></sec><sec sec-type="methods"><title>Methods</title><p>Ten mechanically ventilated patients with acute exacerbation of COPD received four puffs of salmeterol (25 &#x003bc;g/puff). Salmeterol was administered with an MDI adapted to the inspiratory limb of the ventilator circuit using an aerosol cloud enhance spacer. Static and dynamic airway pressures, minimum (R<sub>int</sub>) and maximum (Rrs) inspiratory resistance, and the difference between Rrs and R<sub>int </sub>(&#x00394;R) were measured before and at 15, 30, and 60 minutes as well as at 2, 3, 4, 6, 8, 10, and 12 hours after salmeterol administration. The overall effects of salmeterol on respiratory system mechanics and heart rate during the 12-hour study period were analyzed by nonparametric Wilcoxon signed rank test.</p></sec><sec><title>Results</title><p>Salmeterol caused a significant decrease in dynamic and static airway pressures, R<sub>int</sub>, and Rrs. These changes were evident at 30 minutes and remained significant for 8 hours after salmeterol administration. The duration of bronchodilation varied significantly among patients, lasting in some patients more than 10 hours and wearing off in others in less than 6 hours.</p></sec><sec><title>Conclusions</title><p>It is concluded that four puffs of salmeterol delivered with an MDI and a spacer device induces significant bronchodilation in mechanically ventilated patients with COPD exacerbation, the duration of which is highly variable, precluding definite conclusions in regard to optimum dosing schedules.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Delivery of bronchodilators with metered-dose inhalers (MDIs) in mechanically ventilated patients has become a widespread practice in recent years [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Several studies have shown that MDIs adapted to the inspiratory limb of the ventilator using a compatible spacer device are as effective as nebulizers despite a significantly lower dose of bronchodilator administered with this technique [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Compared with the nebulizer, an MDI has several advantages, such as reliability of dosing, ease of administration, reduced cost, less personnel time needed, and lower risk of contamination [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Although the technique of administration as well as the dose-response curve of bronchodilators in mechanically ventilated patients using an MDI and a spacer device has been examined by several studies [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B15">15</xref>], data in regard to the duration of the bronchodilator response are scarce and restricted to salbutamol [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Furthermore, although the bronchodilator response of long-acting &#x003b2;2-agonists &#x02013; which are considered first-line treatment in symptomatic chronic obstructive pulmonary disease (COPD) [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>] &#x02013; has been studied in stable spontaneously breathing COPD patients [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>], no data exist concerning the effect of long-acting &#x003b2;2-agonists in mechanically ventilated patients with COPD exacerbation. The purpose of the present study, therefore, was to examine the duration of bronchodilation induced by the long-acting &#x003b2;2-agonist salmeterol administered with an MDI and a spacer in a group of mechanically ventilated patients with COPD.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Ten male patients (mean age &#x000b1; standard deviation of 67.8 &#x000b1; 6 years) with COPD, requiring endotracheal intubation and mechanical ventilation to manage acute respiratory failure due to an acute exacerbation of chronic airflow obstruction, were studied. Patients with a diagnosis of bronchial asthma as well as patients with pneumonia, pulmonary edema, refractory hypoxemia, pneumothorax, or excessive airway secretions were excluded. All patients had a previous diagnosis of COPD and met established criteria for this diagnosis [<xref ref-type="bibr" rid="B18">18</xref>]. Their previous pulmonary function data were consistent with severe COPD, with forced expiratory volume in the first second (FEV<sub>1</sub>) of 38% &#x000b1; 4%, forced vital capacity of 56% &#x000b1; 6%, residual volume of 177% &#x000b1; 25%, and total lung capacity of 112% &#x000b1; 7% of predicted values (mean &#x000b1; standard error). The study was approved by the hospital ethics committee, and informed consent was obtained from the patients' next of kin. In cases in which patients regained the capacity to give consent, this was later obtained from them.</p><p>The patients were studied during a period of clinical stability, no more than 72 hours after the onset of mechanical ventilation. All patients were orotracheally intubated (low-pressure cuff endotracheal tube, internal diameter of 8.0 &#x000b1; 0.5 mm, and tube length of 28 &#x000b1; 1 mm), heavily sedated (propofol at a rate of 4 mg/kg per hour and remifentanyl), and ventilated on volume-controlled mode (Evita 2; Draeger, Luebeck, Germany) using settings that minimized dynamic hyperinflation (tidal volume [VT] of 7 to 8 mL/kg, square wave flow-time profile, no end-inspiratory pause, and zero external positive end-expiratory pressure [PEEPe]) and a fractional concentration of inspired oxygen that achieved a hemoglobin saturation of greater than 89%. Minute ventilation was adjusted in each individual by the attending physician in order to maintain normal arterial pH and remained constant throughout the study. The absence of respiratory muscle activity was based on specific criteria, including absence of negative deflection of airway pressure (Paw), stabilization of the Paw waveform, constancy of peak inspiratory pressure from breath to breath, and exponential decline of expiratory flow [<xref ref-type="bibr" rid="B24">24</xref>]. Patient characteristics and baseline ventilator settings are shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics and baseline ventilator settings</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Age, years</td><td align="center">FiO<sub>2</sub></td><td align="center">PaO<sub>2</sub>, mm Hg</td><td align="center">PaCO<sub>2</sub>, mm Hg</td><td align="center">VT, liters</td><td align="center">Fr, breaths per minute</td><td align="center">V'<sub>I</sub>, liters per second</td><td align="center">T<sub>I</sub>/T<sub>TOT</sub></td><td align="center">V<sub>E</sub>, liters per minute</td></tr></thead><tbody><tr><td align="left">67.8 &#x000b1; 6.0</td><td align="center">0.39 &#x000b1; 0.06</td><td align="center">72.8 &#x000b1; 7.1</td><td align="center">59.4 &#x000b1; 3.8</td><td align="center">0.52 &#x000b1; 0.04</td><td align="center">14.6 &#x000b1; 1.6</td><td align="center">0.72 &#x000b1; 0.04</td><td align="center">0.24 &#x000b1; 0.02</td><td align="center">7.5 &#x000b1; 0.9</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#x000b1; standard deviation. FiO<sub>2</sub>, fractional concentration of inspired oxygen; Fr, respiratory frequency; PaCO<sub>2</sub>, partial pressure of arterial carbon dioxide; PaO<sub>2</sub>, partial pressure of arterial oxygen; T<sub>I</sub>/T<sub>TOT</sub>, duty cycle; V<sub>E</sub>, minute ventilation; V'<sub>I</sub>, constant inspiratory flow; VT, tidal volume.</p></table-wrap-foot></table-wrap><p>Flow at the airway opening was measured with a heated pneumotachograph (Hans-Rudolf 3700; Hans Rudolph, Inc., Shawnee, KS, USA) and a differential pressure transducer (Micro-Switch 140PC; Honeywell Sensing and Control, Golden Valley, MN, USA) placed between the endotracheal tube and the Y-piece of the ventilator circuit. Flow was electronically integrated to provide volume. Paws (Micro-Switch 140PC) were measured from a side port between the pneumotachograph and the endotracheal tube. All signals were sampled at 50 Hz (Windaq, Datac Instruments Inc., Akron, OH, USA) and stored on a computer disk for later analysis.</p><p>Each patient received four puffs of salmeterol. Each puff contained 25 &#x003bc;g of salmeterol xinafoate and was given by an MDI canister (Serevent inhaler; Glaxo Smith Kline, Uxbridge, Middlesex, UK) adapted to the inspiratory limb of the ventilator circuit using an aerosol cloud enhancer spacer (Diemolding Healthcare Division, Canastota, NY, USA), whereby the MDI flume is directed away from the patient. The spacer was placed just before the Y-ventilator connector. The canister was shaken before each series of puffs. Each puff was delivered at 20- to 30-second intervals, immediately before initiation of airflow by the ventilator. Inspiratory flow and VT during administration were kept constant to baseline values (Table <xref ref-type="table" rid="T1">1</xref>). All bronchodilators were withheld at least 6 hours before the study. All patients were receiving corticosteroids (1 mg/kg of body weight intravenous prednisolone per day) and this regimen was not modified during the study. None of the patients was on theophylline. Arterial blood gases were measured before and at 4, 8, and 12 hours after drug administration. Arterial oxygen saturation (SaO<sub>2</sub>) was measured continuously using a pulse oxymeter (Critikon, Tampa, FL, USA). All patients were ventilated in a semirecumbent position (which was kept constant throughout the study period), certain nursing interventions (for example, chest physiotherapy and suctioning) were withheld or minimized, and the remaining aspects of patient care (for example, fluids and nutrition) were at the discretion of the treating physician.</p><p>Respiratory system mechanics and heart rate (HR) were assessed before (baseline) and at 15, 30, 60 minutes as well as at 2, 3, 4, 6, 8, 10, and 12 hours after each series of puffs. The mechanical properties of the respiratory system were determined while the patient was ventilated at baseline ventilator settings shown in Table <xref ref-type="table" rid="T1">1</xref> using the occlusion technique, as previously described [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. End-inspiratory static compliance of the respiratory system (Crs, st) as well as minimum (R<sub>int</sub>) and maximum (Rrs) resistance of the respiratory system were computed according to standard formulas [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. The difference between Rrs and R<sub>int </sub>(&#x00394;R), caused by time-constant inequalities and/or viscoelastic behavior (stress relaxation), was also calculated. R<sub>int </sub>and Rrs were corrected for the finite occlusion time of the occlusion valve of the ventilator [<xref ref-type="bibr" rid="B27">27</xref>]. The endotracheal tube resistance was not taken into account since each patient served as his or her own control. The heat and moisture exchanger (HME) of the ventilator circuit was removed before drug administration and reconnected after drug delivery, as previously suggested [<xref ref-type="bibr" rid="B1">1</xref>]. Similarly, the HME was removed prior to all respiratory mechanics measurements. As an index of duration of the resulting bronchodilation, time after salmeterol administration that R<sub>int </sub>remained less than 85% of its baseline value was measured.</p><p>Data concerning the overall effects of salmeterol on respiratory system mechanics and HR during the 12-hour study period were analyzed by nonparametric Wilcoxon signed rank test. Correlation of bronchodilator response to patients' baseline characteristics as well as their baseline respiratory system mechanics was tested by linear regression analysis by using Spearman's correlation coefficients. The changes of postinhalational parameters of respiratory system mechanics from baseline were given in absolute and percentage decrease values. All results are expressed as mean &#x000b1; standard deviation. A <italic>P </italic>value of less than 0.05 was considered statistically significant. The Statistical Package for Social Sciences for Windows version 15.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis.</p></sec><sec><title>Results</title><p>Dynamic and static Paws, respiratory system mechanics, and HR before (time 0) and after salmeterol administration are shown in Table <xref ref-type="table" rid="T2">2</xref>. The administration of 100 &#x003bc;g of salmeterol caused a significant decrease in dynamic and static Paws as well as in R<sub>int</sub>, Rrs, and intrinsic positive end-expiratory pressure (PEEPi) (Wilcoxon signed rank test). The decrease in Rrs was due mainly to a decrease in R<sub>int </sub>while &#x00394;R remained relatively constant throughout the study period. As shown in Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2b</xref>, the effects of salmeterol on R<sub>int</sub>, which reflects 'ohmic' airway resistance, were evident at 30 minutes after drug delivery and remained relatively constant for approximately 8 hours. Except for one patient who did not exhibit any bronchodilator response to salmeterol, in the remaining nine patients mean R<sub>int </sub>changed from baseline by 17.8% &#x000b1; 5.2% at 30 minutes, reaching a peak decrease of 21.6% &#x000b1; 2.8% at 2 hours, while at 8 hours after drug administration a significant decrease of 16.2% &#x000b1; 6.2% was still present (<italic>P </italic>&#x0003c; 0.05 for all values). Individual patient values of R<sub>int </sub>at baseline and at the predefined time points during the 12-hour study period after salmeterol administration are shown in Figure <xref ref-type="fig" rid="F3">3</xref>. Duration of bronchodilator response for each patient, expressed as the time that individual R<sub>int </sub>values remained less than 85% of their corresponding baseline values, is shown in Figure <xref ref-type="fig" rid="F4">4</xref>. Of note, in one patient, a sustained bronchodilator response was still present at 12 hours whereas four patients still exhibited a significant response at 8 hours after salmeterol administration. R<sub>int </sub>remained less than 85% of baseline values for 6 hours in three patients and for 4 hours in one patient, whereas one patient did not exhibit any bronchodilator response to salmeterol. Individual PEEPi and Rrs changes followed the R<sub>int </sub>response in a similar fashion.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Percentage change (&#x00394;-difference %) in peak airway pressure (Ppk), minimum inspiratory resistance (R<sub>int</sub>), maximum inspiratory resistance (Rrs), and intrinsic positive end-expiratory pressure (PEEPi) after salmeterol administration.</p></caption><graphic xlink:href="cc7117-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Effect of salmeterol on airway pressures and inspiratory resistance mean values. <bold>(a) </bold>Mean values (&#x000b1; 1 SD) of peak airway pressure (Ppk) and intrinsic positive end-expiratory pressure (PEEPi) at baseline and up to 12 hours after salmeterol administration. <bold>(b) </bold>Mean values (&#x000b1; 1 SD) of minimum inspiratory resistance (R<sub>int</sub>) and maximum inspiratory resistance (Rrs) at baseline and up to 12 hours after salmeterol administration. *Significantly different from baseline values (<italic>P </italic>&#x0003c; 0.05, Wilcoxon signed rank test). SD, standard deviation.</p></caption><graphic xlink:href="cc7117-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Individual patient values of minimum inspiratory resistance (R<sub>int</sub>) before and after salmeterol administration. Baseline values (before salmeterol) are indicated at time 0. The closed circles connected by the thick solid line represent the mean R<sub>int </sub>value for the whole patient group. -&#x025c6;-: Patient #1; -&#x025a0;-: Patient #2; -x-: Patient #3; -&#x02737;-: Patient #4; -&#x025cb;-: Patient #5; -&#x025cf;-: Patient #6; -&#x025a1;-: Patient #7; -&#x025b3;: Patient #8; --x--: Patient #9; -&#x025c7;-: Patient #10.</p></caption><graphic xlink:href="cc7117-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Time after salmeterol administration that minimum inspiratory resistance (R<sub>int</sub>) remained less than 85% of baseline in each patient.</p></caption><graphic xlink:href="cc7117-4"/></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Airway pressures, respiratory system mechanics, and heart rate before and up to 12 hours after salmeterol administration</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Baseline</td><td align="center">15 minutes</td><td align="center">30 minutes</td><td align="center">1 hour</td><td align="center">2 hours</td><td align="center">3 hours</td><td align="center">4 hours</td><td align="center">6 hours</td><td align="center">8 hours</td><td align="center">10 hours</td><td align="center">12 hours</td></tr></thead><tbody><tr><td align="left">Ppk</td><td align="center">35.0 &#x000b1; 5.1</td><td align="center">33.0 &#x000b1; 5.1<sup>a</sup></td><td align="center">31.4 &#x000b1; 5.0<sup>a</sup></td><td align="center">30.8 &#x000b1; 4.8<sup>a</sup></td><td align="center">30.6 &#x000b1; 4.9<sup>a</sup></td><td align="center">30.4 &#x000b1; 4.9<sup>a</sup></td><td align="center">30.6 &#x000b1; 4.5<sup>a</sup></td><td align="center">30.7 &#x000b1; 4.6<sup>a</sup></td><td align="center">31.4 &#x000b1; 4.5<sup>a</sup></td><td align="center">32.3 &#x000b1; 4.5<sup>a</sup></td><td align="center">33.2 &#x000b1; 4.5<sup>a</sup></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">P<sub>1</sub></td><td align="center">22.3 &#x000b1; 4.1</td><td align="center">21.4 &#x000b1; 4.3<sup>a</sup></td><td align="center">20.7 &#x000b1; 4.4<sup>a</sup></td><td align="center">20.5 &#x000b1; 4.2<sup>a</sup></td><td align="center">20.4 &#x000b1; 4.4<sup>a</sup></td><td align="center">20.2 &#x000b1; 4.1<sup>a</sup></td><td align="center">20.3 &#x000b1; 3.8<sup>a</sup></td><td align="center">20.4 &#x000b1; 3.9<sup>a</sup></td><td align="center">20.5 &#x000b1; 3.6<sup>a</sup></td><td align="center">20.9 &#x000b1; 3.7<sup>a</sup></td><td align="center">21.4 &#x000b1; 3.7<sup>a</sup></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">P<sub>2</sub></td><td align="center">16.7 &#x000b1; 3.1</td><td align="center">15.8 &#x000b1; 2.8<sup>a</sup></td><td align="center">15.3 &#x000b1; 3.1<sup>a</sup></td><td align="center">15.1 &#x000b1; 2.9<sup>a</sup></td><td align="center">15.0 &#x000b1; 3.1<sup>a</sup></td><td align="center">14.9 &#x000b1; 3.2<sup>a</sup></td><td align="center">14.9 &#x000b1; 2.8<sup>a</sup></td><td align="center">15.0 &#x000b1; 2.8<sup>a</sup></td><td align="center">15.2 &#x000b1; 2.7<sup>a</sup></td><td align="center">15.5 &#x000b1; 2.6<sup>a</sup></td><td align="center">16.0 &#x000b1; 2.7</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">PEEPi</td><td align="center">7.1 &#x000b1; 1.6</td><td align="center">6.2 &#x000b1; 1.7<sup>a</sup></td><td align="center">5.5 &#x000b1; 1.9<sup>a</sup></td><td align="center">5.2 &#x000b1; 1.8<sup>a</sup></td><td align="center">5.2 &#x000b1; 1.8<sup>a</sup></td><td align="center">5.1 &#x000b1; 1.8<sup>a</sup></td><td align="center">5.1 &#x000b1; 1.8<sup>a</sup></td><td align="center">5.2 &#x000b1; 1.9<sup>a</sup></td><td align="center">5.4 &#x000b1; 1.8<sup>a</sup></td><td align="center">5.7 &#x000b1; 1.8<sup>a</sup></td><td align="center">6.2 &#x000b1; 1.8<sup>a</sup></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">Rrs</td><td align="center">25.4 &#x000b1; 4.1</td><td align="center">23.8 &#x000b1; 4.4<sup>a</sup></td><td align="center">22.3 &#x000b1; 4.1<sup>a</sup></td><td align="center">21.7 &#x000b1; 3.6<sup>a</sup></td><td align="center">21.6 &#x000b1; 3.6<sup>a</sup></td><td align="center">21.5 &#x000b1; 3.5<sup>a</sup></td><td align="center">21.8 &#x000b1; 3.3<sup>a</sup></td><td align="center">21.6 &#x000b1; 3.6<sup>a</sup></td><td align="center">22.5 &#x000b1; 4.2<sup>a</sup></td><td align="center">23.2 &#x000b1; 4.1<sup>a</sup></td><td align="center">23.9 &#x000b1; 3.8<sup>a</sup></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">R<sub>int</sub></td><td align="center">17.6 &#x000b1; 3.7</td><td align="center">16.1 &#x000b1; 4.0<sup>a</sup></td><td align="center">14.9 &#x000b1; 3.6<sup>a</sup></td><td align="center">14.3 &#x000b1; 3.1<sup>a</sup></td><td align="center">14.2 &#x000b1; 3.0<sup>a</sup></td><td align="center">14.2 &#x000b1; 3.0<sup>a</sup></td><td align="center">14.3 &#x000b1; 3.0<sup>a</sup></td><td align="center">14.3 &#x000b1; 3.0<sup>a</sup></td><td align="center">15.1 &#x000b1; 3.7<sup>a</sup></td><td align="center">16.0 &#x000b1; 3.9<sup>a</sup></td><td align="center">16.4 &#x000b1; 3.4<sup>a</sup></td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">&#x00394;R</td><td align="center">7.7 &#x000b1; 2.2</td><td align="center">7.7 &#x000b1; 2.5</td><td align="center">7.5 &#x000b1; 2.2</td><td align="center">7.5 &#x000b1; 2.2</td><td align="center">7.5 &#x000b1; 2.2</td><td align="center">7.3 &#x000b1; 1.9</td><td align="center">7.5 &#x000b1; 1.9</td><td align="center">7.3 &#x000b1; 2.0</td><td align="center">7.3 &#x000b1; 2.0</td><td align="center">7.2 &#x000b1; 2.0</td><td align="center">7.5 &#x000b1; 2.1</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">Cst, rs</td><td align="center">54.3 &#x000b1; 9.0</td><td align="center">54.2 &#x000b1; 9.0</td><td align="center">53.1 &#x000b1; 7.4</td><td align="center">52.3 &#x000b1; 7.4</td><td align="center">53.0 &#x000b1; 7.4</td><td align="center">53.3 &#x000b1; 7.5</td><td align="center">53.1 &#x000b1; 7.7</td><td align="center">52.7 &#x000b1; 6.7</td><td align="center">52.8 &#x000b1; 6.3</td><td align="center">52.2 &#x000b1; 5.8</td><td align="center">52.2 &#x000b1; 5.8</td></tr><tr><td colspan="12"><hr></hr></td></tr><tr><td align="left">HR</td><td align="center">74.8 &#x000b1; 8.5</td><td align="center">75.0 &#x000b1; 7.3</td><td align="center">74.5 &#x000b1; 6.8</td><td align="center">75.0 &#x000b1; 7.2</td><td align="center">74.5 &#x000b1; 6.2</td><td align="center">73.9 &#x000b1; 7.7</td><td align="center">73.5 &#x000b1; 8.7</td><td align="center">73.1 &#x000b1; 9.6</td><td align="center">73.8 &#x000b1; 8.8</td><td align="center">74.8 &#x000b1; 11.0</td><td align="center">73.4 &#x000b1; 10.2</td></tr></tbody></table><table-wrap-foot><p>Values are presented as mean &#x000b1; standard deviation. <sup>a</sup>Significantly different from baseline values (<italic>P </italic>&#x0003c; 0.05, Wilcoxon signed rank test). <sup>b</sup>Respiratory system mechanics were measured while the patients were on volume control with square wave inspiratory flow-time profile. Crs, st, end-inspiratory static compliance of the respiratory system (mL/cm H<sub>2</sub>O); HR, heart rate (beats per minute); P<sub>1</sub>, airway pressure at the point of zero flow (cm H<sub>2</sub>O); P<sub>2</sub>, plateau pressure (cm H<sub>2</sub>O); PEEPi, intrinsic positive end-expiratory pressure (cm H<sub>2</sub>O); Ppk, peak airway pressure (cm H<sub>2</sub>O); R<sub>int</sub>, minimum inspiratory resistance (cm H<sub>2</sub>O/L per second); Rrs, maximum inspiratory resistance (cm H<sub>2</sub>O/L per second); &#x00394;R, difference between maximum inspiratory resistance and minimum inspiratory resistance (cm H<sub>2</sub>O/L per second).</p></table-wrap-foot></table-wrap><p>Salmeterol administration had no substantial effect on gas exchange. Partial pressure of arterial oxygen (PaO<sub>2</sub>) differed from baseline by 0.9 &#x000b1; 2.8, 1.3 &#x000b1; 3.4, and 2.4 &#x000b1; 4.9 mm Hg at 4, 8, and 12 hours, respectively (<italic>P </italic>&#x0003e; 0.05 for all values, Wilcoxon signed rank test), whereas a small (albeit statistically significant) decrease in PaCO<sub>2 </sub>(partial pressure of arterial carbon dioxide) was noted (-2.8 &#x000b1; 1.3, -3.7 &#x000b1; 1.7, and -4.1 &#x000b1; 2 mm Hg at 4, 8, and 12 hours after salmeterol administration, respectively, <italic>P </italic>&#x0003c; 0.05 for all values, Wilcoxon signed rank test) as the observed bronchodilative effect resulted in improved alveolar ventilation. Changes in Cst, rs and HR were not significant at any time interval after salmeterol administration (Table <xref ref-type="table" rid="T2">2</xref>). SaO<sub>2 </sub>remained constant throughout the study period, indicating that clinically significant changes in PaO<sub>2 </sub>as a result of salmeterol administration did not occur.</p></sec><sec><title>Discussion</title><p>Our work demonstrates that 100 &#x003bc;g of the long-acting &#x003b2;2-agonist salmeterol delivered by MDI and a spacer caused a substantial bronchodilator effect that induced a significant and sustained decrease in inspiratory resistance indices, namely a maximal R<sub>int </sub>and Rrs decrease of 21.6% and 16.2%, respectively. These values compare rather well with the corresponding values in previous studies of short-acting &#x003b2;2-agonists in mechanically ventilated COPD patients, ranging between 18% and 25% for R<sub>int </sub>and between 8% and 15% for Rrs [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B28">28</xref>], while baseline respiratory mechanics in these studies were similar to ours (R<sub>int </sub>of 14 to 21 cm H<sub>2</sub>O/L per second and Rrs of 20 to 26 cm H<sub>2</sub>O/L per second). &#x00394;R remained relatively constant throughout the study, indicating that salmeterol acted by dilating the central airways in a manner similar to salbutamol in previous studies [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Although expiratory resistance was not measured in the present study, this most probably was decreased by salmeterol, as indicated by the significant reduction in PEEPi and end-inspiratory static plateau pressure, which are indirect indices of dynamic hyperinflation. Similarly, although lung volumes were not assessed, the observed reduction in PEEPi could be regarded as an index &#x02013; although an indirect one &#x02013; of a corresponding change in end-expiratory lung volume (that is, a decrease in dynamic hyperinflation). We further showed that the onset of the bronchodilator response was noted at 30 minutes after drug delivery while its duration was quite variable among patients, remaining relatively constant for approximately 6 hours in the majority of our study population.</p><p>It is of interest that the assessment of bronchodilator response to &#x003b2;2-agonists in mechanically ventilated patients with COPD exacerbation has been limited mainly to the short-acting &#x003b2;2-agonist salbutamol. Although the bronchodilator effect of salmeterol has been studied in stable spontaneously breathing COPD patients [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>] (where it has been shown to be effective for up to 12 hours, providing obvious advantages over short-acting therapies), no data exist concerning the effect of salmeterol in mechanically ventilated patients with COPD exacerbation. To the best of our knowledge, this is the first study about the effect of a long-acting bronchodilator on respiratory system mechanics and dynamic hyperinflation in mechanically ventilated COPD patients.</p><p>There are several limitations to our study. Since the optimal dose of inhaled &#x003b2;2-agonists in mechanically ventilated COPD patients has not been established clearly and based on the finding that aerosol deposition in mechanically ventilated patients is substantially lower than in nonintubated patients, higher doses have been recommended for ventilated patients [<xref ref-type="bibr" rid="B29">29</xref>]. Subsequent dose-response studies with salbutamol concluded that a dose of 400 &#x003bc;g ensures the best combination of bronchodilator effect and safety in mechanically ventilated patients with COPD [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In the case of salmeterol, however, due to the complete absence of relevant data, a dose of 100 &#x003bc;g was arbitrarily chosen by extrapolating the results of the salbutamol dose-response studies, in which the delivered dose was twice the dose recommended for nonintubated patients. This, however, does not exclude the possibility that, in an individual patient, higher doses may be necessary in order to achieve maximum bronchodilation. For example, it is not known whether patient 8 would have responded to a higher dose of salmeterol. Hence, in the absence of dose-response studies combined with appropriate pharmacokinetic data in regard to salmeterol administration in mechanically ventilated patients, straightforward interpretation of our results is a matter of discussion.</p><p>In nonintubated spontaneously breathing COPD patients, 50 &#x003bc;g of salmeterol causes a bronchodilator effect lasting at least 12 hours [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. In the majority of our patients, the observed bronchodilator effect remained relatively constant for approximately 6 hours, indicating a reduced duration of the bronchodilator response during invasive mechanical ventilation. This could be explained by the reduced bioavailability of the drug, as observed by Duarte and colleagues [<xref ref-type="bibr" rid="B30">30</xref>] in the case of salbutamol. Furthermore, reduced duration of bronchodilator effect during COPD exacerbation has been observed for short-acting &#x003b2;2-agonists [<xref ref-type="bibr" rid="B31">31</xref>]. A decrease in pulmonary disposition and drug absorption in the setting of increased bronchomotor tone due to airway inflammation has been proposed as a possible underlying mechanism [<xref ref-type="bibr" rid="B32">32</xref>], an observation that could similarly apply to long-acting &#x003b2;2-agonists.</p><p>Propofol has been shown to cause a bronchodilative effect in mechanically ventilated COPD patients when administered as a bolus [<xref ref-type="bibr" rid="B33">33</xref>]. Although our patients were already receiving a continuous propofol infusion at a steady dose for at least 24 hours before study inclusion, the possibility of an additive to salmeterol bronchodilative effect cannot be entirely ruled out.</p><p>A considerable degree of variation in regard to the duration and magnitude of the bronchodilator response was observed. This response was, furthermore, rather unpredictable. Neither individual baseline characteristics or respiratory system mechanics nor the acute bronchodilator response (that is, at 30 minutes after salmeterol administration) was able to predict the duration of the resulting drug effect. The subject of interindividual variation in bronchodilator response to inhaled &#x003b2;2-agonists in COPD patients is a well-known entity. This variation seems to be determined by several factors, like age [<xref ref-type="bibr" rid="B34">34</xref>], the degree of baseline airflow limitation [<xref ref-type="bibr" rid="B35">35</xref>], and smoking status [<xref ref-type="bibr" rid="B36">36</xref>]. Furthermore, a potential role for genetic factors like polymorphisms of the &#x003b2;2-adrenergic receptor gene in determining bronchodilator response in COPD patients has recently been proposed [<xref ref-type="bibr" rid="B37">37</xref>]. Although these observations are limited to short-acting &#x003b2;2-agonists in non-intensive care unit patients and have to be regarded as preliminary evidence awaiting confirmation by larger studies, we believe their implications are nonetheless quite intriguing.</p><p>In our study, a 15% decrease of R<sub>int </sub>from baseline was defined as a significant bronchodilative response. Although there are no established threshold values, previous studies have shown that an Rrs or R<sub>int </sub>decrease of greater than 10% may indicate significant bronchodilator response [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Dhand and colleagues [<xref ref-type="bibr" rid="B15">15</xref>] examined R<sub>int </sub>variability in passively ventilated COPD patients over the course of 1 hour and found that the coefficient of variation among patients ranged from 1.6% to 3.9%. Although R<sub>int </sub>variability over the course of a 12-hour period is not known, it seems highly unlikely that a 15% decrease in R<sub>int </sub>would represent merely a patient's airway caliber variability rather than true bronchodilator response.</p><p>Therefore, according to our findings, it is not possible to propose a fixed dosing interval for salmeterol in mechanically ventilated patients with COPD exacerbation. Instead of the use of a standard dosing regimen, individualization of the dose interval titrated to objective indices of bronchodilation seems to be more prudent. The issue of objectively guided dose titration is probably the most important one for the clinician, whereas it certainly is a matter of debate which indices at which time point could serve as a reliable marker of effective bronchodilation. As shown in Figure <xref ref-type="fig" rid="F2">2a</xref>, we observed a decline in peak airway pressure (P<sub>pk</sub>) of approximately 4 cm H<sub>2</sub>O at 30 minutes after drug administration, a change that one could argue is of clinical relevance and relatively easy to detect at the bedside. However, further studies designed to specifically address these particular issues would certainly provide additional answers.</p></sec><sec><title>Conclusion</title><p>Our study demonstrated that, in mechanically ventilated patients with COPD exacerbation, four puffs of salmeterol delivered by an MDI and a spacer device induced significant bronchodilation. The duration of the observed bronchodilator effect was highly variable and unpredictable among patients. This variability precludes definite guidelines in regard to an optimum dosing schedule, which should be titrated according to objective indices of bronchodilation.</p></sec><sec><title>Key messages</title><p>&#x02022; In mechanically ventilated patients with chronic obstructive pulmonary disease exacerbation, 100 &#x003bc;g of the long-acting &#x003b2;2-agonist salmeterol delivered by metered-dose inhaler and a spacer caused a significant bronchodilator effect.</p><p>&#x02022; This effect was evident at 30 minutes after drug delivery and remained relatively constant for approximately 8 hours.</p><p>&#x02022; Due to substantial interpatient variability, no definite conclusions in regard to the optimum dosing schedules of salmeterol can be drawn.</p></sec><sec><title>Abbreviations</title><p>COPD: chronic obstructive pulmonary disease; Crs, st: end-inspiratory static compliance of the respiratory system; HME: heat and moisture exchanger; HR: heart rate; MDI: metered-dose inhaler; PaO<sub>2</sub>: partial pressure of arterial oxygen; Paw: airway pressure; PEEPi: intrinsic positive end-expiratory pressure; R<sub>int</sub>: minimum inspiratory resistance; Rrs: maximum inspiratory resistance; &#x00394;R: difference between maximum inspiratory resistance and minimum inspiratory resistance; SaO<sub>2</sub>: arterial oxygen saturation; VT: tidal volume.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>DG conceived the study, participated in its design, and revised the final version of the manuscript for important intellectual content. PM participated in study design and data collection and drafted the manuscript. GG participated in data collection and helped to draft the manuscript. ML performed the statistical analysis and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhand</surname><given-names>R</given-names></name></person-group><article-title>Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients</article-title><source>Respir Care</source><year>2005</year><volume>50</volume><fpage>1331</fpage><lpage>1334</lpage><comment>discussion 1334-1335.</comment><pub-id pub-id-type="pmid">16185369</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhand</surname><given-names>R</given-names></name></person-group><article-title>Basic techniques for aerosol delivery during mechanical ventilation</article-title><source>Respir Care</source><year>2004</year><volume>49</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">15165296</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhand</surname><given-names>R</given-names></name><name><surname>Tobin</surname><given-names>MJ</given-names></name></person-group><article-title>Inhaled bronchodilator therapy in mechanically ventilated patients</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9230718</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>A</given-names></name></person-group><article-title>Inhaled bronchodilator administration during mechanical ventilation</article-title><source>Respir Care</source><year>2004</year><volume>49</volume><fpage>623</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">15165297</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Georgopoulos</surname><given-names>D</given-names></name><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Kondili</surname><given-names>E</given-names></name><name><surname>Klimathianaki</surname><given-names>M</given-names></name></person-group><article-title>Bronchodilator delivery with metered-dose inhaler during mechanical ventilation</article-title><source>Crit Care</source><year>2000</year><volume>4</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">11094505</pub-id><pub-id pub-id-type="doi">10.1186/cc698</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhand</surname><given-names>R</given-names></name></person-group><article-title>Inhalation therapy in invasive and noninvasive mechanical ventilation</article-title><source>Curr Opin Crit Care</source><year>2007</year><volume>13</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17198046</pub-id><pub-id pub-id-type="doi">10.1097/MCC.0b013e328012e022</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Summer</surname><given-names>W</given-names></name><name><surname>Elston</surname><given-names>R</given-names></name><name><surname>Tharpe</surname><given-names>L</given-names></name><name><surname>Nelson</surname><given-names>S</given-names></name><name><surname>Haponik</surname><given-names>EF</given-names></name></person-group><article-title>Aerosol bronchodilator delivery methods: relative impact on pulmonary function and cost of respiratory care</article-title><source>Arch Intern Med</source><year>1989</year><volume>149</volume><fpage>618</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">2919938</pub-id><pub-id pub-id-type="doi">10.1001/archinte.149.3.618</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowton</surname><given-names>DL</given-names></name><name><surname>Goldsmith</surname><given-names>WM</given-names></name><name><surname>Haponik</surname><given-names>EF</given-names></name></person-group><article-title>Substitution of metered-dose inhalers for hand nebulizers: success and cost-saving in a large, acute care hospital</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">1346514</pub-id><pub-id pub-id-type="doi">10.1378/chest.101.2.305</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alvine</surname><given-names>GF</given-names></name><name><surname>Rodgers</surname><given-names>P</given-names></name><name><surname>Fitzsimmons</surname><given-names>KM</given-names></name><name><surname>Ahrens</surname><given-names>RC</given-names></name></person-group><article-title>Disposable jet nebulizers; how reliable are they?</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>316</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">1735247</pub-id><pub-id pub-id-type="doi">10.1378/chest.101.2.316</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamill</surname><given-names>RJ</given-names></name><name><surname>Houston</surname><given-names>ED</given-names></name><name><surname>Georghiu</surname><given-names>PR</given-names></name><name><surname>Wright</surname><given-names>CE</given-names></name><name><surname>Koza</surname><given-names>MA</given-names></name><name><surname>Cadle</surname><given-names>RM</given-names></name><name><surname>Goeptert</surname><given-names>PA</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Zenon</surname><given-names>GJ</given-names></name><name><surname>Clarridge</surname><given-names>JE</given-names></name></person-group><article-title>An outbreak of <italic>Burkholderia </italic>formerly <italic>Pseudomonas</italic>) <italic>cepacia </italic>respiratory tract colonisation and infection associated with nebulized albuterol therapy</article-title><source>Ann Intern Med</source><year>1995</year><volume>122</volume><fpage>762</fpage><lpage>766</lpage><pub-id pub-id-type="pmid">7536401</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Katsanoulas</surname><given-names>K</given-names></name><name><surname>Anastasaki</surname><given-names>M</given-names></name><name><surname>Askitopoulou</surname><given-names>E</given-names></name><name><surname>Georgopoulos</surname><given-names>D</given-names></name></person-group><article-title>Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of end-inspiratory pause</article-title><source>Eur Respir J</source><year>1998</year><volume>12</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">9701432</pub-id><pub-id pub-id-type="doi">10.1183/09031936.98.12010165</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Katsanoulas</surname><given-names>K</given-names></name><name><surname>Anastasaki</surname><given-names>M</given-names></name><name><surname>Hoing</surname><given-names>S</given-names></name><name><surname>Georgopoulos</surname><given-names>D</given-names></name></person-group><article-title>Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of tidal volume</article-title><source>Intensive Care Med</source><year>1999</year><volume>25</volume><fpage>1215</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">10654204</pub-id><pub-id pub-id-type="doi">10.1007/s001340051049</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Prinianakis</surname><given-names>G</given-names></name><name><surname>Kondili</surname><given-names>E</given-names></name><name><surname>Georgopoulos</surname><given-names>D</given-names></name></person-group><article-title>Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: influence of flow pattern</article-title><source>Eur Respir J</source><year>2000</year><volume>16</volume><fpage>263</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">10968501</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.16b13.x</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Prinianakis</surname><given-names>G</given-names></name><name><surname>Kondili</surname><given-names>E</given-names></name><name><surname>Georgopoulos</surname><given-names>D</given-names></name></person-group><article-title>Effect of inspiratory flow rate on beta<sub>2</sub>-agonist induced bronchodilation in mechanically ventilated COPD patients</article-title><source>Intensive Care Med</source><year>2001</year><volume>27</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">11280671</pub-id><pub-id pub-id-type="doi">10.1007/s001340000714</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhand</surname><given-names>R</given-names></name><name><surname>Duarte</surname><given-names>AG</given-names></name><name><surname>Jubran</surname><given-names>A</given-names></name><name><surname>Jenne</surname><given-names>JW</given-names></name><name><surname>Fink</surname><given-names>JB</given-names></name><name><surname>Fahey</surname><given-names>PJ</given-names></name><name><surname>Tobin</surname><given-names>MJ</given-names></name></person-group><article-title>Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">8756811</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>AG</given-names></name><name><surname>Momii</surname><given-names>K</given-names></name><name><surname>Bidani</surname><given-names>A</given-names></name></person-group><article-title>Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: comparison of magnitude and duration of response</article-title><source>Respir Care</source><year>2000</year><volume>45</volume><fpage>817</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">10926377</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mouloudi</surname><given-names>E</given-names></name><name><surname>Malliotakis</surname><given-names>C</given-names></name><name><surname>Kondili</surname><given-names>E</given-names></name><name><surname>Kafetzakis</surname><given-names>A</given-names></name><name><surname>Georgopoulos</surname><given-names>D</given-names></name></person-group><article-title>Duration of salbutamol-induced bronchodilation delivered by metered-dose inhaler in mechanically ventilated COPD patients</article-title><source>Monaldi Arch Chest Dis</source><year>2001</year><volume>56</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">11665496</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>B</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Chavannes</surname><given-names>N</given-names></name><name><surname>Dillard</surname><given-names>T</given-names></name><name><surname>Fahy</surname><given-names>B</given-names></name><name><surname>Fein</surname><given-names>A</given-names></name><name><surname>Heffner</surname><given-names>J</given-names></name><name><surname>Lareau</surname><given-names>S</given-names></name><name><surname>Meek</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>McNicholas</surname><given-names>W</given-names></name><name><surname>Muris</surname><given-names>J</given-names></name><name><surname>Austegard</surname><given-names>E</given-names></name><name><surname>Pauwels</surname><given-names>R</given-names></name><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Siafakas</surname><given-names>N</given-names></name><name><surname>Tiep</surname><given-names>B</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Wouters</surname><given-names>E</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name><collab>for the ATS/ERS Task Force</collab></person-group><article-title>Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>932</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">15219010</pub-id><pub-id pub-id-type="doi">10.1183/09031936.04.00014304</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Buist</surname><given-names>SA</given-names></name><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><name><surname>van Weel</surname><given-names>C</given-names></name><name><surname>Zielinski</surname><given-names>J</given-names></name></person-group><article-title>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><fpage>532</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">17507545</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200703-456SO</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celik</surname><given-names>G</given-names></name><name><surname>Kayacan</surname><given-names>O</given-names></name><name><surname>Beder</surname><given-names>S</given-names></name><name><surname>Durmaz</surname><given-names>G</given-names></name></person-group><article-title>Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action</article-title><source>Respiration</source><year>1999</year><volume>66</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">10516540</pub-id><pub-id pub-id-type="doi">10.1159/000029427</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name><name><surname>Santangelo</surname><given-names>G</given-names></name><name><surname>Vinciguerra</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>D'Amato</surname><given-names>G</given-names></name></person-group><article-title>Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study</article-title><source>Respir Med</source><year>1995</year><volume>89</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">7638371</pub-id><pub-id pub-id-type="doi">10.1016/0954-6111(95)90008-X</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rennard</surname><given-names>SI</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name><name><surname>Broughton</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Wisniewski</surname><given-names>M</given-names></name><name><surname>Rickard</surname><given-names>K</given-names></name></person-group><article-title>Use of a long-acting inhaled &#x003b2;2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">11316640</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Barbee</surname><given-names>RA</given-names></name><name><surname>Goldman</surname><given-names>MD</given-names></name><name><surname>Gross</surname><given-names>NJ</given-names></name><name><surname>Wisniewski</surname><given-names>ME</given-names></name><name><surname>Yancey</surname><given-names>SW</given-names></name><name><surname>Zakes</surname><given-names>BA</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name></person-group><article-title>Efficacy of salmeterol xinafoate in the treatment of COPD</article-title><source>Chest</source><year>1999</year><volume>115</volume><fpage>957</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">10208192</pub-id><pub-id pub-id-type="doi">10.1378/chest.115.4.957</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prechter</surname><given-names>CG</given-names></name><name><surname>Nelson</surname><given-names>SB</given-names></name><name><surname>Hubmayr</surname><given-names>RD</given-names></name></person-group><article-title>The ventilatory recruitment threshold for carbon dioxide</article-title><source>Am Rev Respir Dis</source><year>1990</year><volume>141</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">2106815</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottfried</surname><given-names>SB</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Higgs</surname><given-names>BD</given-names></name><name><surname>Zocchi</surname><given-names>L</given-names></name><name><surname>Grassino</surname><given-names>A</given-names></name><name><surname>Milic-Emili</surname><given-names>J</given-names></name></person-group><article-title>Respiratory mechanics in mechanically ventilated patients with respiratory failure</article-title><source>J Appl Physiol</source><year>1985</year><volume>58</volume><fpage>1849</fpage><lpage>1858</lpage><pub-id pub-id-type="pmid">4008405</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>JHT</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Milic-Emili</surname><given-names>J</given-names></name></person-group><article-title>Analysis of the behaviour of the respiratory system with constant inspiratory flow</article-title><source>J Appl Physiol</source><year>1985</year><volume>58</volume><fpage>1840</fpage><lpage>1848</lpage><pub-id pub-id-type="pmid">4008404</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kochi</surname><given-names>T</given-names></name><name><surname>Okubo</surname><given-names>S</given-names></name><name><surname>Zin</surname><given-names>WA</given-names></name><name><surname>Milic-Emili</surname><given-names>J</given-names></name></person-group><article-title>Flow and volume dependence of pulmonary mechanics in anaesthetized cats</article-title><source>J Appl Physiol</source><year>1988</year><volume>64</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">3356662</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>A</given-names></name><name><surname>Lazaro</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Aragon</surname><given-names>C</given-names></name><name><surname>Cerda</surname><given-names>E</given-names></name></person-group><article-title>Bronchodilators in patients with chronic obstructive pulmonary disease on mechanical ventilation: utilization of metered-dose inhalers</article-title><source>Am Rev Respir Dis</source><year>1990</year><volume>141</volume><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">2136979</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><article-title>Aerosol consensus statement. Consensus conference on aerosol delivery</article-title><source>Chest</source><year>1991</year><volume>100</volume><fpage>1106</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">1914568</pub-id><pub-id pub-id-type="doi">10.1378/chest.100.4.1106</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>AG</given-names></name><name><surname>Dhand</surname><given-names>R</given-names></name><name><surname>Ralston</surname><given-names>R</given-names></name><name><surname>Fink</surname><given-names>J</given-names></name><name><surname>Fahey</surname><given-names>P</given-names></name><name><surname>Tobin</surname><given-names>MJ</given-names></name><name><surname>Jenne</surname><given-names>JW</given-names></name></person-group><article-title>Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>1658</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">8970351</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernasconi</surname><given-names>M</given-names></name><name><surname>Brandolese</surname><given-names>R</given-names></name><name><surname>Poggi</surname><given-names>R</given-names></name><name><surname>Manzin</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name></person-group><article-title>Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction</article-title><source>Intensive Care Med</source><year>1990</year><volume>16</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">2332537</pub-id><pub-id pub-id-type="doi">10.1007/BF02575304</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Testi</surname><given-names>R</given-names></name><name><surname>Matera</surname><given-names>MG</given-names></name></person-group><article-title>Clinical pharmacokinetics of salmeterol</article-title><source>Clin Pharmacokinet</source><year>2002</year><volume>41</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11825095</pub-id><pub-id pub-id-type="doi">10.2165/00003088-200241010-00003</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>G</given-names></name><name><surname>Dell'Utri</surname><given-names>D</given-names></name><name><surname>Vilardi</surname><given-names>V</given-names></name><name><surname>De Blasi</surname><given-names>RA</given-names></name><name><surname>Pelaia</surname><given-names>P</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Bufi</surname><given-names>M</given-names></name><name><surname>Rosa</surname><given-names>G</given-names></name><name><surname>Gasparetto</surname><given-names>A</given-names></name></person-group><article-title>Propofol induces bronchodilation in mechanically ventilated chronic obstructive pulmonary disease (COPD) patients</article-title><source>Acta Anaesthesiol Scand</source><year>1993</year><volume>37</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">8424280</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Omenaas</surname><given-names>ER</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><name><surname>Bakke</surname><given-names>PS</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name></person-group><article-title>Post-bronchodilator spirometry reference values in adults and implications for disease management</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>1316</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">16556696</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200601-023OC</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name></person-group><article-title>Bronchodilator reversibility testing in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>659</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">12885978</pub-id><pub-id pub-id-type="doi">10.1136/thorax.58.8.659</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Bakke</surname><given-names>PS</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><name><surname>Humerfelt</surname><given-names>S</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name></person-group><article-title>Bronchodilator reversibility testing in an adult general population: the importance of smoking and anthropometrical variables on the response to a beta2-agonist</article-title><source>Pulm Pharmacol Ther</source><year>2006</year><volume>19</volume><fpage>272</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">16169762</pub-id><pub-id pub-id-type="doi">10.1016/j.pupt.2005.07.006</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hizawa</surname><given-names>N</given-names></name><name><surname>Makita</surname><given-names>H</given-names></name><name><surname>Nasuhara</surname><given-names>Y</given-names></name><name><surname>Betsuyaku</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name></person-group><article-title>&#x003b2;2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>1485</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">17890463</pub-id><pub-id pub-id-type="doi">10.1378/chest.07-1103</pub-id></citation></ref></ref-list></back></article>


